These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 2173392

  • 41. Phase II study of high-dose epirubicin in untreated patients with small-cell lung cancer.
    Macchiarini P, Danesi R, Mariotti R, Marchetti A, Fazzi P, Bevilacqua G, Mariani M, Giuntini C, Del Tacca M, Angeletti CA.
    Am J Clin Oncol; 1990 Aug; 13(4):302-7. PubMed ID: 2165738
    [Abstract] [Full Text] [Related]

  • 42. High-dose induction chemotherapy with cyclophosphamide, etoposide, and cisplatin for extensive-stage small-cell lung cancer.
    Johnson DH, DeLeo MJ, Hande KR, Wolff SN, Hainsworth JD, Greco FA.
    J Clin Oncol; 1987 May; 5(5):703-9. PubMed ID: 3033161
    [Abstract] [Full Text] [Related]

  • 43. [Pilot study of dose intensive weekly chemotherapy followed by cisplatin plus etoposide with concurrent thoracic irradiation for limited-disease small-cell lung cancer. West Japan Thoracic Oncology Group].
    Isobe T, Fukuoka M, Negoro S, Sugiura T, Kawahara M, Kudoh S, Araki J, Nakagawa K, Yokozaki M, Yamakido M, Ariyoshi Y.
    Gan To Kagaku Ryoho; 2000 Jul; 27(8):1091-6. PubMed ID: 10945001
    [Abstract] [Full Text] [Related]

  • 44. [Dose-response effect of drugs in the chemotherapy of small-cell bronchial carcinoma].
    Kostić D, Jelić S, Radulović S.
    Srp Arh Celok Lek; 2000 Jul; 128(3-4):75-9. PubMed ID: 10932613
    [Abstract] [Full Text] [Related]

  • 45. Etoposide, carboplatin, cyclophosphamide and vincristine in previously untreated patients with small-cell lung cancer.
    Bishop JF, Kefford R, Raghavan D, Zalcberg J, Stuart-Harris R, Ball D, Olver IN, Friedlander M, Bull C, Yuen K.
    Cancer Chemother Pharmacol; 1990 Jul; 25(5):367-70. PubMed ID: 2155064
    [Abstract] [Full Text] [Related]

  • 46. High-dose cisplatin, etoposide, and cyclophosphamide with autologous stem cell reinfusion in patients with responsive metastatic or high-risk primary breast cancer.
    Somlo G, Doroshow JH, Forman SJ, Leong LA, Margolin KA, Morgan RJ, Raschko JW, Akman SA, Ahn C, Sniecinski I.
    Cancer; 1994 Jan 01; 73(1):125-34. PubMed ID: 7903906
    [Abstract] [Full Text] [Related]

  • 47. Multicenter phase II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited-stage small-cell lung cancer.
    Bremnes RM, Sundstrøm S, Vilsvik J, Aasebø U, Norwegian Lung Cancer Study Group.
    J Clin Oncol; 2001 Aug 01; 19(15):3532-8. PubMed ID: 11481360
    [Abstract] [Full Text] [Related]

  • 48. Cisplatin/etoposide chemotherapy combined with twice daily thoracic radiotherapy for limited small-cell lung cancer: a clinical phase II trial.
    Chen GY, Jiang GL, Wang LJ, Qian H, Fu XL, Yang H, Wu KL, Zhao S.
    Int J Radiat Oncol Biol Phys; 2005 Jan 01; 61(1):70-5. PubMed ID: 15629596
    [Abstract] [Full Text] [Related]

  • 49. Multi-institutional phase I/II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited-stage small-cell lung carcinoma.
    Levitan N, Dowlati A, Shina D, Craffey M, Mackay W, DeVore R, Jett J, Remick SC, Chang A, Johnson D.
    J Clin Oncol; 2000 Mar 01; 18(5):1102-9. PubMed ID: 10694563
    [Abstract] [Full Text] [Related]

  • 50. Cyclophosphamide, vincristine, cisplatin, VP-16 and radiation therapy in extensive small-cell lung cancer. A Southwest Oncology Group Study.
    Collins C, Higano CS, Livingston RB, Griffin BR, Keppen MD, Miller TP.
    Cancer Chemother Pharmacol; 1989 Mar 01; 24(2):128-32. PubMed ID: 2543513
    [Abstract] [Full Text] [Related]

  • 51. Etoposide and split-dose cisplatin in small-cell lung cancer.
    Wilke H, Achterrath W, Schmoll HJ, Gunzer U, Preusser P, Lenaz L.
    Am J Clin Oncol; 1988 Oct 01; 11(5):572-8. PubMed ID: 2845770
    [Abstract] [Full Text] [Related]

  • 52. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
    Sundstrøm S, Bremnes RM, Kaasa S, Aasebø U, Aamdal S, Norwegian Lung Cancer Study Group.
    Lung Cancer; 2005 May 01; 48(2):251-61. PubMed ID: 15829326
    [Abstract] [Full Text] [Related]

  • 53. Cisplatin plus etoposide chemotherapy followed by thoracic irradiation and paclitaxel plus cisplatin consolidation therapy for patients with limited stage small cell lung carcinoma.
    Kakolyris S, Agelidou A, Androulakis N, Tsaroucha E, Kouroussis Ch, Agelidou M, Karvounis N, Veslemes M, Christophylakis Ch, Argyraki A, Geroyianni A, Georgoulias V.
    Lung Cancer; 2006 Jul 01; 53(1):59-65. PubMed ID: 16716447
    [Abstract] [Full Text] [Related]

  • 54. Phase II trial of up-front accelerated thoracic radiotherapy combined with chemotherapy and optional up-front prophylactic cranial irradiation in limited small-cell lung cancer. Groupe d'Oncologie Thoracique des Régions Alpines.
    Hügli A, Moro D, Mermillod B, Bolla M, Alberto P, Bonnefoi H, Miralbell R.
    J Clin Oncol; 2000 Apr 01; 18(8):1662-7. PubMed ID: 10764426
    [Abstract] [Full Text] [Related]

  • 55. Randomized phase II trial of high-dose 4'-epi-doxorubicin + cyclophosphamide versus high-dose 4'-epi-doxorubicin + cisplatin in previously untreated patients with extensive small cell lung cancer.
    Kánitz E, Kolaric K, Jassem J, Mechl Z, Pawlicki M, Ringwald G, Rolski J, Schoket Z, Vukas D, Kaplan E.
    Oncology; 1992 Apr 01; 49(5):327-32. PubMed ID: 1326734
    [Abstract] [Full Text] [Related]

  • 56. Cisplatin, etoposide, and paclitaxel in the treatment of patients with extensive small-cell lung carcinoma.
    Glisson BS, Kurie JM, Perez-Soler R, Fox NJ, Murphy WK, Fossella FV, Lee JS, Ross MB, Nyberg DA, Pisters KM, Shin DM, Hong WK.
    J Clin Oncol; 1999 Aug 01; 17(8):2309-15. PubMed ID: 10561292
    [Abstract] [Full Text] [Related]

  • 57. Combination chemotherapy with vincristine, epirubicin and cyclophosphamide in small cell lung carcinoma. Polish Lung Cancer Cooperative Group.
    Jassem J, Karnicka-Młodkowska H, Drozd-Lula M, Strug A, Pilarska-Machowicz A, Michalski A, Kowal E, Moś-Antkowiak R, Zych J.
    Eur J Cancer; 1992 Aug 01; 28(2-3):473-6. PubMed ID: 1317199
    [Abstract] [Full Text] [Related]

  • 58. A phase I trial of a 5-day schedule of intravenous topotecan and etoposide in previously untreated patients with small-cell lung cancer.
    O'Neill P, Clark PI, Smith D, Marshall E, Hannigan K, Ross G.
    Oncology; 2001 Aug 01; 61 Suppl 1():25-9. PubMed ID: 11598411
    [Abstract] [Full Text] [Related]

  • 59. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G, Marschke R, Camoriano JK, Sorensen JM, Sloan JA, Richardson RL.
    Cancer J Sci Am; 1997 Aug 01; 3(5):297-302. PubMed ID: 9327154
    [Abstract] [Full Text] [Related]

  • 60. Phase II study of an intensive combination chemotherapy with cisplatin, adriamycin, etoposide and cyclophosphamide (CAVE) in small cell lung cancer.
    Sculier JP, Klastersky J, Becquart D, Vandermoten G, van Houtte P, Rocmans P, Thiriaux J, Longeval E, Ravez P, Libert P.
    Eur J Cancer Clin Oncol; 1988 Mar 01; 24(3):519-26. PubMed ID: 2838289
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.